BeiGene gets EU backing for neck and head cancer treatment
Source: SeekingAlpha
2025-05-27 09:06:12 ET
More on BeiGene
- BeiGene, Ltd., Soon To Be BeOne Medicines: New Name And New Profit
- BeiGene, Ltd. (ONC) Q1 2025 Earnings Call Transcript
- BeiGene: Q4 Results Impress With Positive Earnings Expected In 2025
- Drugmakers rebound after White House eases fears over Trump’s drug pricing order
- BeiGene targets $4.9B-$5.3B revenue for 2025 with strong BRUKINSA and pipeline growth
Read the full article on Seeking Alpha
For further details see:
BeiGene gets EU backing for neck and head cancer treatment
BeiGene
NASDAQ: BEIGF
BEIGF Trading
0.0% G/L:
$23.75 Last:
100 Volume:
$23.75 Open:
BEIGF Latest News
BEIGF Stock Data
$38,603,023,416
747,457,849
N/A
299
N/A
Biotechnology & Life Sciences
Healthcare
CH
Basel
